What people report

Semaglutide reviews: what people report

Read 41 people, 3 sitesPublished by PepVault

Of the 41 people whose Semaglutide write-ups we read, 33 describe a change they wanted (33 a change in weight or appetite; 2 a calmer gut), 1 noticed nothing and 28 describe something unwanted.

What people report

33 of the 41 people describe at least one change they wanted. Each bar counts the people who named anything in that group, once each, out of all 41; the line under it says what they named, and how many named it. Each took it on its own.

  • Weight and appetite33 of 41weight loss 22 · less appetite 16 · less food noise or fewer cravings 2
  • Gut2 of 41a calmer gut 2
  • Thinking, memory and mood1 of 41clearer, quicker thinking 1
  • Other8 of 41lower blood sugar 8

What went wrong or did nothing

28 of the 41 people describe something they didn’t want, and 1 noticed nothing at all.

  • Noticed nothing at all1 of 41
  • Gut19 of 41nausea or an upset stomach 14 · diarrhoea 4 · burping or wind 3 · vomiting 3 · constipation 2 · gallbladder pain 2 · heartburn 2 · bloating 1 · pancreatitis 1
  • Energy6 of 41tiredness 6
  • Sleep2 of 41worse sleep 2
  • Thinking, memory and mood2 of 41low mood or loss of pleasure 2
  • Weight and appetite1 of 41muscle loss 1
  • Skin and hair1 of 41itching 1
  • Other6 of 41a higher resting heart rate 2 · feeling ill 2 · dizziness or low blood pressure 1 · food tasting different 1

Your report

Taken Semaglutide? What did you notice?

One tap to start. About 30 seconds, no account.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Semaglutide? Keep your own record

Log each dose and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

When people say it begins

6 of the 41 people say when they first noticed something; 35 don’t.

  • On the first day3 of 41
  • In the first week3 of 41

What people took it for

22 of the 41 people say what they took it for; 19 don’t.

  • Type 2 diabetes14 of 41
  • Weight loss5 of 41
  • Health and longevity2 of 41
  • Appetite control1 of 41

How it’s thought to work

Shown in people

Semaglutide is a long-lasting copy of GLP-1, a gut hormone released after a meal. It slows the stomach, makes a meal fill you sooner, quiets hunger in the brain and helps the pancreas release insulin when blood sugar rises. Controlled trials in people showed it lowers body weight, blood sugar and the risk of heart attacks and strokes; it is approved as Ozempic and Rybelsus for type two diabetes and as Wegovy for weight loss.

Sources: Wilding et al., 2021: STEP 1, weight in adults without diabetes; Marso et al., 2016: SUSTAIN-6, heart events in type two diabetes; Lincoff et al., 2023: SELECT, heart events in obesity without diabetes

What studies show

Our research section has 31 study pages on Semaglutide: 30 in people and 1 in mice.

The first large trial for weight loss gave 1961 adults without diabetes a weekly shot of semaglutide or a dummy shot for 68 weeks (STEP 1); their weight fell by 14.9% on average, against 2.4% on the dummy shot, and nausea and diarrhea were the commonest side effects.

Where the reports run ahead of the studies

Weight loss, less appetite, lower blood sugar and an upset stomach are what the controlled trials found too. Where the reports run ahead: 2 of the 41 people, both with long-standing bowel trouble, say their gut settled on semaglutide. No controlled trial has tested semaglutide for irritable bowel; one study of health records has looked at the drug class in it (PubMed, searched November 19, 2026).

Where the reports come from

41 people on 13 pages across 3 sites, written from August 2019 to August 2026. Read on November 19, 2026.

The largest single site, rapamycin.news, gave 23 of the 41.

Peptide Critic, which runs its forum, also runs a shop on its own site that sells injection pens and supplies, not peptides.

Millions of people take semaglutide on a prescription, and the few who write on these forums are a small corner of them who chose to write. The Diabetes UK posters took Ozempic on a prescription for type two diabetes; many rapamycin.news posters took small doses of the Rybelsus tablet for health rather than weight. We read the open threads with the most first-person reports and stopped there.

Read and not counted

  • Doctors and clinicians on rapamycin.news who give it to patients: Reports on patients from the people who prescribe it, not a person’s own, so not counted, even where they also wrote of their own use.
  • A rapamycin.news member who supplies GLP-1 drugs to clients: The seller’s side of the counter, so not counted.
  • Reports about someone else (a cousin, a friend, a wife, a friend’s rat): Second-hand; only a person’s own report counts.
  • Posts about price, supply, pharmacies and where to buy: Most posts in these threads; nothing noticed was said.
  • Posts where the change could not be put on semaglutide: A poster who could not tell whether night-time trips to the toilet came from the drug or from high blood sugar, and posts naming the drug class without saying which drug.
  • Drugs.com user reviews: The site refuses automated reads, so it was skipped.
  • Reddit and X: Not part of this count.

How we counted

We read every open write-up we could find by people who took Semaglutide, on its own page, and counted each person once however often they posted, including those who noticed nothing. Sellers, clinics, shop reviews and anyone who earns on a sale are not counted, and neither is a search result’s snippet; the list above names what we read and left out. Write-ups lean positive, because people who notice nothing rarely write about it and expecting an effect can produce one.

Spot an error? feedback@pepvault.app. How we research. This page reports what people say; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Semaglutide? Keep your own record

Log each dose and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo